Christopher Yea - Aug 22, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Aug 22, 2024
Transactions value $
-$23,758
Form type
4
Date filed
8/26/2024, 07:58 PM
Previous filing
Aug 21, 2024
Next filing
Nov 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +3.13K +3.7% 87.6K Aug 22, 2024 Direct F1
transaction KALV Common Stock Sale -$23.8K -1.92K -2.19% $12.40 85.7K Aug 23, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -3.13K -6.25% $0.00 46.9K Aug 22, 2024 Common Stock 3.13K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.